We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener

Session

Lung
Digital Poster
Clinical
Post-Operative Radiotherapy in completely resected Non-Small Cell Lung Cancer and N2 involvement
André Miranda Pires, Portugal
PO-1148
SBRT for lung cancer: outcomes from biopsy-proven and empirically treated lung lesions
Laura Guzmán Gómez, Spain
PO-1149
Prognostic role of [18F]FDG PET-CT after induction chemotherapy for locally advanced Non Small Lung Cancer
Andrea Masarykova, Slovakia
PO-1150
Long non-coding RNA NEAT1 levels expression associate with local recurrence in lung cancer patients
Imanol Paguey Garrido, Spain
PO-1151
Analysis of chest wall toxicity predictors in lung SBRT. 3-fraction schemes for peripheral lesions?
Diego Aldave, Spain
PO-1152
Preliminary mono-institutional report of stereotactic body radiotherapy for lung oligometastases
Francesco Cuccia, Italy
PO-1153
Respiratory admissions following RT in relation to pulmonary function and lung doses in lung cancer
Fei Sun, United Kingdom
PO-1154
Real world radiotherapy protocol compliance for patients with Stage I-III Non-Small Cell Lung cancer
Xiaoshui Huang, Australia
PO-1155
Temporal muscle thickness as a potential biomarker of OS in NSCLC patients with BM treated with SRT
Giovanni Gadducci, Italy
PO-1156
Prediction of delayed lymphopenia after chemoradiotherapy in non-small cell lung cancer
Byung-Hee Kang, Korea Republic of
PO-1157
Validation of a spatial dose pattern predicting pulmonary toxicity in patients treated with VMAT for a lung cancer
Vincent Bourbonne, France
PO-1158
Prognostic role of pro-inflammatory cytokines in multimodal treatment of inoperable stage III NSCLC
Lukas Käsmann, Germany
PO-1159
An automated segmentation algorithm for GTV delineation in SBRT of the lung, a proof of concept.
Ahmed Allam Mohamed, Germany
PO-1160
Feasibility of stereotactic body radiotherapy of (ultra)central lung tumors using an 1.5 T MR-linac
Laura Merckel, The Netherlands
PO-1161
DLCA-R: Variation in elderly stage III NSCLC treated with definitive chemoradiation.
Edith Dieleman, The Netherlands
PO-1162
Incidence of cardiovascular events in advanced NSCLC patients treated with chemo-radiotherapy.
Carmen Corral Fernandez, Spain
PO-1163
Clinical evaluation of an interactive deep-learning assisted contouring method for target contouring
Michael J Trimpl, Germany
PO-1164
Dosimetric parameters in hypofractionated radiotherapy in NSCLC cohort during SARS-COV-2 pandemia
Mari Angeles González Ruiz, Spain
PO-1165
Treatment patterns and efficacy of durvalumab maintenance after CRT in real-world NSCLC patients
Julian Taugner, Germany
PO-1166
Radiomic approach for prediction of response to radiochemotherapy in stage III NSCLC
Sara Ramella, Italy
PO-1167
Moderately hypofractionated radiotherapy in non-small cell lung cancer
Irene Fajardo-Paneque, Spain
PO-1168
30 Gy single dose stereotactic radiation therapy in a series of patients with lung oligometastasis
Dimitri Anzellini, Italy
PO-1169
Between a rock and heart place – cardiac sparing in MRI-guided lung SBRT
Luuk van der Pol, The Netherlands
PO-1170
Two-stage CT-based radiomic signature to predict the efficacy of immunotherapy
Pei Yang, China
PO-1171
Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy
Joyce Lodeweges, The Netherlands
PO-1172
Previous pneumectomy is a risk factor of severe radiation pneumonitis after IMRT for lung cancer
Saori Tatsuno, Japan
PO-1173
3-weekly paclitaxel-carboplatin with radiation for stage III NSCLC – option during COVID-19 pandemic
Henry Wong, China, Hong Kong Special Administrative Region
PO-1174
Influence of Charlson comorbidity index in hypofractionated radiotherapy treatment in lung cancer.
Mari Angeles González Ruiz, Spain
PO-1175
Duration of acute esophageal toxicity in RT-CHT for NSCLC with different fractionation schedules
Joanna Socha, Poland
PO-1176
A heart valves contouring atlas on average intensity projection 4D-CT for lung cancer radiotherapy
Joanna Socha, Poland
PO-1177
Treatment of stage III NSCLC in a developing country. Needs for improvement.
Elvisa Kozma, Albania
PO-1178
Radiation induced pneumonitis during COVID-19: artificial intelligence for differential diagnosis.
Edy Ippolito, Italy
PO-1179
Machine Learning to Predict Survival in Small Cell Lung Cancer: A Pilot Study
Melek Yakar, Turkey
PO-1180
HYPOFRACTIONATION IN NSCLC AS THE NEW STANDARD OF CARE DURING SARS-CoV-2 PANDEMIA.
Victoria Vera Barragán, Spain
PO-1181
Mean heart dose predicts survival of NSCLC patients treated with chemoradiotherapy and durvalumab
Eva Ćirić, Slovenia
PO-1183
Pathological response after neoadjuvant chemotherapy versus chemoradiotherapy in stage III NSCLC
Diego Muñoz Guglielmetti, Spain
PO-1184
Development of a nomogram for predicting brain metastasis of small cell lung cancer
qing hou, China
PO-1185
Treatment outcomes of stereotactic body radiotherapy for lung cancer according to tumor appearances
Yasushi Hamamoto, Japan
PO-1186
Overall survival prediction in NSCLC: a radiomic approach with a multi-VOI analysis
Sonia Silipigni, Italy
PO-1187
Adjuvant Involved Field versus Elective Nodal Irradiation for N2 NSCLC: a dosimetric study
Mohammed Mohammed, Lebanon
PO-1188
Stereotactic radiotherapy for lung oligometastases from colorectal cancer
Andrei Fodor, Italy
PO-1189
Lung lesions treated with CyberKnife: An Indian single centre experience
Ajay Sasidharan, India
PO-1190
Immunotherapy and radiation (iRT) in a 'Real-life' setting. Analysis on safety and effectiveness
Antonio Angrisani, Italy
PO-1191
Safety analysis of Stereotactic Body Radiotherapy 8 fractions of 7,5 Gy for Ultracentral Lung Tumors
Eduardo Baena, Spain
PO-1192
The impact of driver mutations on the pathologic response to Chemoradiation (CRT) in LA-NSCLC
Sarit Appel, Israel
PO-1193
A predictive model for OS in patients treated with Stereotactic Radiotherapy for early-stage NSCLC
Paolo Borghetti, Italy
PO-1194
Residual MTV after chemoradiotherapy ± immune checkpoint inhibition for inoperable stage III NSCLC
Julian Taugner, Germany
PO-1195
Role of prophylactic cranial irradiation in limited and extensive-stage small cell lung cancer
Yu Jin Lim, Korea Republic of
PO-1196
Plan complexity as an independent outcome predictor of lung cancer patients treated with SBRT
Chenguang Li, China
PO-1197
Changes in radical radiotherapy for lung cancer patients in the UK during the COVID-19 pandemic.
Kathryn Banfill, United Kingdom
PO-1198
Cardiac disease and tumour below T7 confer poorer prognosis following radical radiotherapy for NSCLC
Amy Colori, United Kingdom
PO-1199
Development and validation of two Australian models to predict 2-year survival in stage I-III NSCLC
Shalini Vinod, Australia
PO-1200
Importance of coronary calcium score in patients with locally advanced non-small cell lung cancer
Agon Olloni , Denmark
PO-1201
Proton Beam Therapy for Stage I and Lymph Node-Negative Stage IIA Non-Small Cell Lung Cancer
Tomoyuki Asao, Japan
PO-1202
lung-perfusion-spect contribution in lung cancer radiotherapy planning process
Simone Baroni, Italy
PO-1203
Adjuvant immunotherapy after concurrent chemoradiotherapy for stage 3 NSCLC, outcomes from a large cancer centre
Fei Sun, United Kingdom
PO-1204